Use of pharmacokinetics in the coagulation factor treatment of patients with haemophilia

Haemophilia

Volumn 11, Issue 6, 2005, Pages 571-582

  Shapiro, Amy D ^a   Korth Bradley, J ^b   Poon, M C ^c  

^a INDIANA HEMOPHILIA AND THROMBOSIS CENTER   (United States)

^b PFIZER INC   (United States)

^c UNIVERSITY OF CALGARY   (Canada)

Author keywords

Coagulation products; Dosage; Factor IX; Factor VIII; Haemophilia; Pharmacokinetics

Indexed keywords

ACTIVATED PROTHROMBIN COMPLEX; BLOOD CLOTTING FACTOR; BLOOD CLOTTING FACTOR 8; BLOOD CLOTTING FACTOR 9; RECOMBINANT BLOOD CLOTTING FACTOR 7A; RECOMBINANT BLOOD CLOTTING FACTOR 8; RECOMBINANT BLOOD CLOTTING FACTOR 9;

AREA UNDER THE CURVE; CLINICAL TRIAL; CONTINUOUS INFUSION; COST CONTROL; COST EFFECTIVENESS ANALYSIS; DISEASE SEVERITY; DOSE CALCULATION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG COST; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG HALF LIFE; HEMOPHILIA; HEMOPHILIA A; HEMOPHILIA B; HUMAN; MEAN RESIDENCE TIME; OPTIMAL DRUG DOSE; PRIORITY JOURNAL; REVIEW; SINGLE DRUG DOSE; SUBSTITUTION THERAPY;

BLOOD SPECIMEN COLLECTION; CHILD; COAGULANTS; DRUG ADMINISTRATION SCHEDULE; FACTOR IX; FACTOR VIII; HEMOPHILIA A; HUMANS; INFUSIONS, PARENTERAL; SOFTWARE; TERMINOLOGY;

EID: 27744605148     PISSN: 13518216     EISSN: 13652516     Source Type: Journal    
DOI: 10.1111/j.1365-2516.2005.01149.x     Document Type: Review

References (38)

1. Human Genetics Programme, Management of Non-communicable Diseases, World Health Organization. Delivery of Treatment for Haemophilia. Report of a joint WHO/WFH/ISTH Meeting, London, UK, 11-13 February 2002. Available at: http://www.wfh.org/Content_Documents/Other_publications/ WHO-WFH-ISTH_meeting.pdf, 2002: 1-16.
2. Rickard KA. Guidelines for therapy and optimal dosages of coagulation factors for treatment of bleeding and surgery in haemophilia. Haemophilia 1995;1(Suppl. 1): 8-13.
3. Roberts HR, Eberst ME. Current management of hemophilia B. Hematol Oncol Clin North Am 1993; 7: 1269-80.
4. White G, Shapiro A, Ragni M et al. Clinical evaluation of recombinant factor IX. Semin Hematol 1998; 35 (Suppl. 2): 33-8.
5. Ewenstein BM, Joist JH, Shapiro AD et al. Pharmacokinetic analysis of plasma-derived and recombinant FIX concentrates in previously treated patients with moderate or severe hemophilia B. Transfusion 2002; 42: 190-7.
6. Poon MC, Lillicrap D, Hensman C, Card R, Scully MF. Recombinant factor IX recovery and inhibitor safety: a Canadian post-licensure surveillance study. Thromb Haemost 2002; 87: 431-5.
7. White GC, Courter S, Bray GL, Lee M, Gomperts ED, The Recombinate Previously Treated Patient Study Group. A multicenter study of recombinant factor VIII (Recombinate™) in previously treated patients with hemophilia A. Thromb Haemost 1997; 77: 660-7.
8. Morfini M, Longo G, Messori A et al. Pharmacokinetic properties of recombinant factor VIII compared with a monoclonally purified concentrate (Hemofil® M). Thromb Haemost 1992; 68: 433-5.
9. Fukui H, Yoshioka A, Shima M et al. Clinical evaluation of recombinant human factor VIII (BAY w 6240) in the treatment of hemophilia A. Int J Hematol 1991; 54: 419-27.
10. Fijnvandraat K, Berntorp E, ten Cate JW et al. Recombinant, B-domain deleted factor VIII (r-VIII SQ): pharmacokinetics and initial safety aspects in hemophilia A patients. Thromb Haemost 1997; 77: 298-302.
11. Lee M, Morfini M, Schulman S, Ingerslev J, and the Factor VIII/Factor IX Scientific and Standardization Committee of the International Society for Thrombosis and Haemostasis. Scientific and Standardization Committee Communication. The Design and Analysis of Pharmacokinetic Studies of Coagulation Factors. On behalf of the Subcommittee on Factor VIII and Factor IX of the Scientific and Standardization Committee of the International Society on Thrombosis and Haemostasis. Available at: http://www.med.unc.edu/isth/ssc/communications/factor8and9/ fviiipharmaco.pdf, 2001: 1-9.
12. Shargel L, Yu A. Applied Biopharmaceutics and Pharmacokinetics. Stamford, CT, USA: Appleton & Lange, 1999.
13. Bjorkman S, Berntorp E. Pharmacokinetics of coagulation factors: clinical relevance for patients with haemophilia. Clin Pharmacokinet 2001; 40: 815-32.
14. Morfini M, Lee M, Messori A. The design and analysis of half-life and recovery studies for factor VIII and factor IX. Factor VIII/Factor IX Scientific and Standardization Committee of the International Society for Thrombosis and Haemostasis. Thromb Haemost 1991; 66: 384-6.
15. Berntorp E, Bjorkman S, Carlsson M, Lethagen S, Nilsson IM. Biochemical and in vivo properties of high purity factor IX concentrates. Thromb Haemost 1993; 70: 768-73.
16. Bjorkman S, Carlsson M, Berntorp E. Pharmacokinetics of factor IX in patients with haemophilia B. Methodological aspects and physiological interpretation. Eur J Clin Pharmacol 1994; 46: 325-32.
17. Berntorp E, Björkman S. The pharmacokinetics of clotting factor therapy. Haemophilia 2003; 9: 353-9.
18. Mikaelsson M, Oswaldsson U, Jankowski MA. Measurement of factor VIII activity of B-domain deleted recombinant factor VIII. Semin Hematol 2001; 38: 13-23.
19. Laub PB, Gallo JM. NCOMP - a windows-based computer program for noncompartmental analysis of pharmacokinetic data. J Pharm Sci 1996; 85: 393-5.
20. Miller GJ, Howarth DJ, Attfield JC et al. Haemostasic factors in human peripheral afferent lymph. Thromb Haemost 2000; 83: 427-32.
21. Bond M, Jankowski M, Patel H et al. Biochemical characterization of recombinant factor IX. Semin Hematol 1998; 35(Suppl. 2): 11-7.
22. Roth DA, Kessler CM, Pasi KJ, Rup B, Courter SG, Tubridy KL. Human recombinant factor IX: safety and efficacy studies in hemophilia B patients previously treated with plasma-derived factor IX concentrates. Blood 2001; 98: 3600-6.
23. Ragni MV, Pasi KJ, White GC et al. Use of recombinant factor IX in subjects with haemophilia B undergoing surgery. Haemophilia 2002; 8: 91-7.
24. Kim HC, McMillan CW, White GC, Bergman GE, Horton MW, Saidi P. Purified factor IX using monoclonal immunoaffinity technique: clinical trials in hemophilia B and comparison to prothrombin complex concentrates. Blood 1992; 79: 568-75.
25. Shapiro AD, White GC II, Kim HC, Lusher JM, Bergman GE. Efficacy and safety of monoclonal antibody purified factor IX concentrate in haemophilia B patients undergoing surgical procedures. Haemophilia 1997; 3: 247-53.
26. Björkman S, Shapiro AD, Berntorp E. Pharmacokinetics of recombinant factor IX in relation to age of the patient: implications for dosing in prophylaxis. Haemophilia 2001; 7: 133-9.
27. White GC, Shapiro AD, Kurczynski EM, Kim HC, The Mononine Study Group, Variability of in vivo recovery of factor IX after infusion of monoclonal antibody purified factor IX concentrates in patients with hemophilia B. Thromb Haemost 1995; 73: 779-84.
28. Carlsson M, Berntorp E, Björkman S, Lethagen S, Ljung R. Improved cost-effectiveness by pharmacokinetic dosing of factor VIII in prophylactic treatment of haemophilia A. Haemophilia 1997; 3: 96-101.
29. Barnes C, Lillicrap D, Blanchette V et al. Novel and clinically significant factors influencing the pharmacokinetic variability of recombinant factor VIII (Kogenate-FS) in children. Blood 2004; 104 (abstract 3991).
30. Shapiro AD, Di Paola J, Cohen A et al. The safety and efficacy of recombinant human blood coagulation factor IX in previously untreated patients with severe or moderately severe hemophilia B. Blood 2005; 105: 518-25.
31. Björkman S. Prophylactic dosing of factor VIII and factor IX from a clinical pharmacokinetic perspective. Haemophilia 2003; 9 (Suppl. 1): 101-10.
32. Carlsson M, Björkman S, Berntorp E. Multidose pharmacokinetics of factor IX: implications for dosing in prophylaxis. Haemophilia 1998; 4: 83-8.
33. Batorova A, Martinowitz U. Continuous infusion of coagulation factors. Haemophilia 2002; 8: 170-7.
34. Schulman S. Continuous infusion. Haemophilia 2003; 9: 368-75.
35. Schulman S, Wallensten R, White B, Smith OP. Efficacy of a high purity, chemically treated and nanofiltered factor IX concentrate for continuous infusion in haemophilia patients undergoing surgery. Haemophilia 1999; 5: 96-100.
36. Batorova A, Martinowitz U. Intermittent injections vs. continuous infusion of factor VIII in haemophilia patients undergoing major surgery. Br J Haematol 2000; 110: 715-20.
37. Chowdary P, Dasani H, Jones JAH et al. Recombinant factor IX (BeneFix®) by adjusted continuous infusion: a study of stability, sterility and clinical experience. Haemophilia 2001; 7: 140-5.
38. Hoots WK, Leissinger C, Stabler S et al. Continuous intravenous infusion of a plasma-derived factor IX concentrate (Mononine®) in haemophilia B. Haemophilia 2003; 9: 164-72.